1. Ono Pharmaceutical. ONO Receives a Manufacturing and Marketing Approval for Velexbru® tablet 80 mg, a BTK inhibitor, for treatment of recurrent or refractory primary central nervous system lymphoma in Japan [media release]. https://www.ono.co.jp/eng/news/pdf/sm_cn200325.pdf. Accessed 25 Mar 2020.
2. Ono Pharmaceutical Co. VELEXBRUⓇ (Tirabrutinib) 80 mg tablets: Japanese prescribing information. 2020. https://www.pmda.go.jp/. Accessed 14 Apr 2020.
3. Ono Pharmaceutical. ONO submits an application for Manufacturing and Marketing Approval in Japan for tirabrutinib hydrochloride (ONO-4059), a BTK inhibitor, for the treatment of Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma [media release]. https://www.ono.co.jp/eng/news/pdf/sm_cn191127.pdf. Accessed 27 Nov 2019.
4. Ono Pharmaceutical. ONO and Gilead announce exclusive license agreement to develop BTK inhibitor, ONO-4059, for the treatment of B-cell alignancies and other diseases [media release]. https://www.ono.co.jp/eng/news/pdf/sm_cn141219.pdf. Accessed 19 Dec 2014.
5. Liclican A, Serafini L, Xing W, et al. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on- and off- target inhibition. Biochim Biophys Acta Gen Subj. 2020;1864(4):129531.